You can buy or sell Nevro and other stocks, options, ETFs, and crypto commission-free!
Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. Read More It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
Redwood City, California
52 Week High
52 Week Low
Guru FocusMar 21
Nevro and Avanos Leading Charge to Opioid-Free Pain Treatments
Nevro Corp. (NVRO) is among a host of public and private companies marketing or developing medical devices to treat pain. These companies are striving to develop alternatives to opioids for the some 50 million people in the U.S. that experience chronic pain daily or almost daily. The opioid crisis has been well documented. Every day, more than 130 people in the country die after overdosing on opioids, according to the National Institute for Drug Abuse. These include prescription pain medications, heroin an...
PR NewswireMar 21
Why 2019 U.S. Medical Device Market Is Expected to Exceed Last Year Revenues
PALM BEACH, Florida, March 21, 2019 /PRNewswire/ -- A recent article in a medical device industry periodical, INN, said that: "2018 has been an important year for the medical device industry as M&A, technology and regulatory catalysts have impacted the market.
Nevro Corp. Stock Quote (U.S.: NYSE)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nevro (NVRO) and NuVasive (NUVA). Nevro (NVRO) Morgan ...[...] Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Nevro (NVRO) delivered earnings and revenue surprises of -88.24% and 0.53%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock? Nevro Co...
Expected May 6, After Hours